Skip to main content
. Author manuscript; available in PMC: 2011 Feb 2.
Published in final edited form as: Mol Cancer Ther. 2010 Feb 2;9(2):268. doi: 10.1158/1535-7163.MCT-09-0765

Table 1.

Aurora kinase inhibitors in clinical trials*

Inhibitor AURKA inhibition AURKB inhibition AURKC inhibition Manufacturer Clinical Status
AZD1152 + + Astra Zeneca Phase I
VX-680 + + + Vertex/Merck Discontinued
MLN8054 + + Millinnium Discontinued
MLN8237 + + Millinnium Phase II
PHA-680632 + + Nerviano Preclinical
PHA-739358 + + + Nerviano Phase II
Hesperidin + Boehringer-Ingelhiem Preclinical
ZM447439 + + Astra Zeneca Phase I
JNJ-770621 + + Johnson & Johnson Preclinical
SU6668 + + Pfizer Discontinued
CCT129202 + + + Chroma Therapeutics Ltd. Preclinical
AT9283 + + Astrex Therapeutics Phase I
MP529 + + Supregen Preclinical
SNS314 + + + Sunesis Pharmaceuticals Phase I
R763 + Rigel Pharmaceuticals Phase I
ENMD2076 + + EntreMed Phase I
XL228 + + + Exelixis Phase I
TTP607 + + + TransTech Pharma Phase I
PF-03814735 + + Pfizer Phase I
CYC116 + + + Cyclacel Phase I
*

The source of data is http://www.clinicaltrial.gov